Flumatinib Mesylate

甲磺酸氟马替尼

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameFlumatinib Mesylate
Drug Alias Name豪森昕福HH-GV-678HHGV-678
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, Chronic
Global Approved IndicationsLeukemia, Myelogenous, Chronic
Approved Indications in ChinaLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2019/11/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
Inactive CompaniesJiangsu Haosen Medical Research Institute Co LtdJiangsu Hengrui Medicine Co Ltd
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsLeukemia, Myeloid, Chronic-Phase

Other Information

ATC CodeL01XE
Related LinksDrugBank